scholarly journals Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy

2016 ◽  
Vol 6 (7) ◽  
pp. e217-e217 ◽  
Author(s):  
H Brath ◽  
P M Paldánius ◽  
G Bader ◽  
W M Kolaczynski ◽  
P M Nilsson
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Drug Therapy ◽  
Glycemic Control ◽  
Post Hoc Analysis ◽  
World Regions ◽  
Post Hoc

Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis

2018 ◽  
Vol 24 ◽  
pp. 80-81
Author(s):  
Konstantinos Toulis ◽  
Krishna Gokhale ◽  
G. Neil Thomas ◽  
Wasim Hanif ◽  
Krishnarajah Nirantharakumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Post Hoc Analysis ◽  
Receptor Agonists ◽  
Post Hoc

scholarly journals Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review

2015 ◽  
Vol 8 ◽  
pp. CMED.S20906 ◽  
Author(s):  
Andreas Liebl ◽  
Kamlesh Khunti ◽  
Domingo Orozco-Beltran ◽  
Jean-Francois Yale
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Health Economic ◽  
Type 2 Diabetes Mellitus ◽  
Drug Therapy ◽  
Glycemic Control ◽  
Cost Effective ◽  
Treatment Intensification ◽  
Total Cost

Type 2 diabetes mellitus (T2D) is a growing healthcare burden primarily due to long-term complications. Strict glycemic control helps in preventing complications, and early introduction of insulin may be more cost-effective than maintaining patients on multiple oral agents. This is an expert opinion review based on English peer-reviewed articles (2000–2012) to discuss the health economic consequences of T2D treatment intensification. T2D costs are driven by inpatient care for treatment of diabetes complications (40%–60% of total cost), with drug therapy for glycemic control representing 18% of the total cost. Insulin therapy provides the most improved glycemic control and reduction of complications, although hypoglycemia and weight gain may occur. Early treatment intensification with insulin analogs in patients with poor glycemic control appears to be cost-effective and improves clinical outcomes. Key Messages • Type 2 diabetes mellitus is a growing burden on healthcare services. • Despite the high cost of drug therapy versus diet and lifestyle interventions, treatment intensification with insulin analog therapy is a cost-effective strategy for improving clinical outcomes in patients with poor glycemic control.

Impact of Race/Ethnicity on the Efficacy and Safety of Commonly Used Insulin Regimens: A Post Hoc Analysis of Clinical Trials in Type 2 Diabetes Mellitus

2010 ◽  
Vol 16 (5) ◽  
pp. 818-828 ◽  
Author(s):  
Jaime Davidson ◽  
Lyndon Lacaya ◽  
Honghua Jiang ◽  
Cory Heilmann ◽  
Jamie Scism-Bacon ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Efficacy And Safety ◽  
Post Hoc Analysis ◽  
Race Ethnicity ◽  
Post Hoc

scholarly journals The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Tomoya Mita ◽  
Naoto Katakami ◽  
Toshihiko Shiraiwa ◽  
Hidenori Yoshii ◽  
Masahiko Gosho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Treatment Group ◽  
Group Versus ◽  
Intima Media Thickness ◽  
Carotid Imt ◽  
Post Hoc Analysis ◽  
Post Hoc

Background. The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the regression of carotid IMT remains largely unknown. The present study aimed to clarify whether sitagliptin, DPP-4 inhibitor, could regress carotid intima-media thickness (IMT) in insulin-treated patients with type 2 diabetes mellitus (T2DM). Methods. This is an exploratory analysis of a randomized trial in which we investigated the effect of sitagliptin on the progression of carotid IMT in insulin-treated patients with T2DM. Here, we compared the efficacy of sitagliptin treatment on the number of patients who showed regression of carotid IMT of ≥0.10 mm in a post hoc analysis. Results. The percentages of the number of the patients who showed regression of mean-IMT-CCA (28.9% in the sitagliptin group versus 16.4% in the conventional group, P = 0.022) and left max-IMT-CCA (43.0% in the sitagliptin group versus 26.2% in the conventional group, P = 0.007), but not right max-IMT-CCA, were higher in the sitagliptin treatment group compared with those in the non-DPP-4 inhibitor treatment group. In multiple logistic regression analysis, sitagliptin treatment significantly achieved higher target attainment of mean-IMT-CCA ≥0.10 mm and right and left max-IMT-CCA ≥0.10 mm compared to conventional treatment. Conclusions. Our data suggested that DPP-4 inhibitors were associated with the regression of carotid atherosclerosis in insulin-treated T2DM patients. This study has been registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000007396).

Smoking and prevalence of nocturia in Japanese patients with type 2 diabetes mellitus: a post-hoc analysis of The Dogo Study

2016 ◽  
Vol 36 (5) ◽  
pp. 1336-1341 ◽  
Author(s):  
Shinya Furukawa ◽  
Takenori Sakai ◽  
Tetsuji Niiya ◽  
Hiroaki Miyaoka ◽  
Teruki Miyake ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Japanese Patients ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document